Sales & Marketing at Cadila Pharmaceuticals Limited, bringing over 27 years of experience across pharmaceutical sales, ...

Sun Pharmaceutical Industries and LIB Therapeutics Inc. announced an exclusive licensing agreement granting the Indian pharma ...

Sun Pharma lerodalcibep rights cover markets outside the US and China. Regulatory rollout and undisclosed economics now ...

- Sun Pharma borrowed $10 billion to acquire Organon OGN0.00%, a $6.2 billion women's health business, doubling its size ...

Indian pharma stocks, including Sun Pharma and Aurobindo Pharma, are in focus after the US exempted India and 19 other ...

Pharma sector stocks such as Sun Pharma, Dr Reddy’s, Cipla, Biocon, Shilpa Medicare, Zydus Life and Hester Bio are in focus ...

Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been ...

Sun Pharma has entered an exclusive agreement with LIB Therapeutics to commercialise Lerodalcibep across markets outside the US and China, gaining access to a US$ 3.7 billion PCSK9 market.

India, Sept. 28 -- High cholesterol is one of those problems that most people know about and far fewer manage well. Statins ...

Sun Pharmaceutical Industries Limited and LIB Therapeutics have announced an exclusive global licensing, commercialization and manufacturing agreement for lerodalcibep, under which Sun Pharma will ...

Sun Pharma inks exclusive licensing with LIB Therapeutics to commercialize lerodalcibep worldwide (excluding U.S. and China) ...

Sun Pharma partners with LIB Therapeutics for exclusive rights to PCSK9 inhibitor lerodalcibep. A strategic expansion into the global cardiovascular market.